CTOs on the Move

Hospital Physician Partners

www.hppartners.com

 
As one of the largest and fastest-growing Emergency and Hospital Medicine groups in the nation, we partner with more than 5,000 world-class providers who treat more than 6 million patients annually. Physician-led, our team consists of motivated, personable, highly qualified people interested in putting the patient first. We’re committed to doing the right thing for the patients, physicians, and hospitals we serve. Which is why 98% of our physicians recommend us to colleagues and friends. William C. Schumacher, M.D., a board certified emergency medicine physician, formally founded the Schumacher Group in 1994. The philosophy behind Schumacher Group`s founding was based ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Sonus USA

Sonus USA is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kalispell Regional Medical Center

Kalispell Regional Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Kalispell Regional Medical Center is based in Kalispell, MT. You can find more information on Kalispell Regional Medical Center at www.krmc.org

Tekia

Tekia is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.

Amedisys

Amedisys is a leading home health and hospice care company focused on bringing home the continuum of care. We deliver personalized home health and hospice care to thousands of patients and their families, in the comfort of their own homes. Our care teams deliver personalized home health and hospice care to approximately 380,000 patients each year. Amedisys is a post-acute care partner to more than 2,233 hospitals and 61,900 physicians across the country. We provide the care that is best for our patients, whether that is home-based recovery and rehabilitation after an operation or injury, care focused on empowering them to manage a chronic disease, palliative care for those with a terminal illness, or hospice care at the end of life. Amedisys is a recognized innovator, being one of the first in the industry to equip its clinicians with point-of-care laptop technology and referring physicians with an internet portal that enables real-time coordination of patient care seamlessly. Amedisys also has the industry`s first-ever nationwide Care Transitions program, designed to reduce unnecessary hospital readmissions through patient and caregiver health coaching and care coordination, which starts in the hospital and continues throughout completion of the patient`s home health plan of care.